OJJAARA
Total Payments
$3.2M
Transactions
12,638
Doctors
5,139
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.8M | 9,746 | 4,475 |
| 2023 | $397,414 | 2,892 | 2,139 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.6M | 467 | 50.1% |
| Unspecified | $960,330 | 3 | 30.2% |
| Food and Beverage | $322,099 | 11,725 | 10.1% |
| Travel and Lodging | $229,637 | 395 | 7.2% |
| Consulting Fee | $57,073 | 41 | 1.8% |
| Space rental or facility fees (teaching hospital only) | $19,500 | 5 | 0.6% |
| Education | $121.50 | 2 | 0.0% |
Payments by Type
General
$2.2M
12,635 transactions
Research
$960,330
3 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| 0000000000000000000000000000000000000000000000000000000000000000221641 | GlaxoSmithKline, LLC. | $960,330 | 0 |
Top Doctors Receiving Payments for OJJAARA — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Medical Oncology | Bolivar, MO | $28,901 | 26 |
| , NP | Nurse Practitioner | Pueblo, CO | $28,557 | 46 |
| , MD | Hematology & Oncology | Wichita, KS | $28,531 | 17 |
| , MD | Medical Oncology | Orange, CA | $27,936 | 12 |
| , MD | Hematology & Oncology | Dayton, OH | $27,693 | 21 |
| , MD | Internal Medicine | Dallas, TX | $26,068 | 26 |
| , M.D | Hematology & Oncology | Sandusky, OH | $25,275 | 10 |
| , MD | Hematology & Oncology | Dix Hills, NY | $23,988 | 10 |
| , MD | Internal Medicine | Charleston, SC | $23,546 | 13 |
| , FNP-C | Nurse Practitioner | Detroit, MI | $22,981 | 33 |
| , MD | Hematology & Oncology | Fort Lauderdale, FL | $21,507 | 17 |
| , M.D | Hospice and Palliative Medicine | San Antonio, TX | $19,565 | 13 |
| , MD | Hematology & Oncology | Nashville, TN | $19,081 | 14 |
| , MD | Medical Oncology | Columbus, OH | $18,345 | 12 |
| , M.D | Internal Medicine | Loma Linda, CA | $17,972 | 8 |
| , MD | Internal Medicine | Hato Rey, PR | $16,738 | 9 |
| , M.D | Specialist | Columbia, MD | $16,406 | 13 |
| , M.D | Hematology & Oncology | Fort Sam Houston, TX | $16,188 | 6 |
| , MD | Hematology & Oncology | Arlington, TX | $15,805 | 17 |
| , N.P | Acute Care | Los Angeles, CA | $15,394 | 21 |
| , M.D | Internal Medicine | York, ME | $14,877 | 11 |
| , M.D | Hematology & Oncology | Birmingham, AL | $14,355 | 16 |
| , M.D | Internal Medicine | Englewood, CO | $14,096 | 13 |
| , MD | Medical Oncology | Syracuse, NY | $11,426 | 18 |
| , M.D | Hematology | Charlotte, NC | $11,256 | 6 |
Ad
Manufacturing Companies
- GlaxoSmithKline, LLC. $3.2M
Product Information
- Type Drug
- Total Payments $3.2M
- Total Doctors 5,139
- Transactions 12,638
About OJJAARA
OJJAARA is a drug associated with $3.2M in payments to 5,139 healthcare providers, recorded across 12,638 transactions in the CMS Open Payments database. The primary manufacturer is GlaxoSmithKline, LLC..
Payment data is available from 2023 to 2024. In 2024, $2.8M was paid across 9,746 transactions to 4,475 doctors.
The most common payment nature for OJJAARA is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.6M, 50.1% of total).
OJJAARA is associated with 1 research study, including "0000000000000000000000000000000000000000000000000000000000000000221641" ($960,330).